HIV & AIDS Information :: Lopinavir/ritonavir cuts malaria risk in children with HIVPosted: March 8, 2012
Dr Achan concluded that children treated with LPV/r-based regimen had a significantly lower risk of getting malaria compared to children on an NNRTI-based regimen as a result of three potential mechanisms:
The pharmacokinetic effect of LPV/r on lumefantrine leading to a prolonged ‘post-treatment’ prophylactic effect after treatment with AL, and as such is the main driver of the outcome.
To a lesser extent the direct antimalarial effect of LPV/r; and
The potential antiparasitic synergy between LPV/r and lumefantrine.
These findings, she noted, suggest a role for ‘pharmaco-enhancement’ as a tool to help reduce the burden of malaria in high endemic settings among HIV-infected individuals.